Thus, targeting TREM2 or modulating its pathway could provide a strategic point of intervention to alter the immune landscape in HCC, potentially improving patient outcomes in immunotherapy and other therapeutic approaches. The gene discussed is TREM2; the disease is hepatocellular carcinoma.